Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer | CLINICAL LUNG CANCER |